AML typical mutations (CEBPA, FLT3, NPM1) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecular.

Blood Adv · 2025 · PMC11732582 · PMID 39388660

Europe PMC DOI

hedged sentence

0.0670

closest p · 1.3× alpha

0.0670

boldest claim

The sentences

showed a trendP = .067so close (0.05 < p ≤ 0.1)

mutCFN patients who received chemotherapy (n = 12) showed a trend toward longer OS than those who did not (n = 9; 25 vs 9 months; P = .067; supplemental Figure 4 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.